Chongqing Kangning v. Conrex Pharmaceutical Corp.

Superior Court of Pennsylvania·Decided April 19, 2021·No. 939 EDA 2020·Unpublished

Opinion

NON-PRECEDENTIAL DECISION - SEE SUPERIOR COURT I.O.P. 65.37

CHONGQING KANGNING : IN THE SUPERIOR COURT OF BIOENGINEERING CO., LTD : PENNSYLVANIA :

Appellant :

:

:

v. :

:

: No. 939 EDA 2020

CONREX PHARMACEUTICAL CORP :

Appeal from the Order Entered February 20, 2020 In the Court of Common Pleas of Chester County Civil Division at No(s):

No. 2019-08925-CT

BEFORE: KUNSELMAN, J., NICHOLS, J., and PELLEGRINI, J.* MEMORANDUM BY NICHOLS, J.: FILED: APRIL 19, 2021 Appellant Chongquing Kangning Bioengineering Co., Ltd., appeals from the order overruling its preliminary objections, which requested arbitration on the counterclaims filed by Appellee Conrex Pharmaceutical Corp.1 Appellant contends that the trial court erred by not recognizing that the two agreements at issue are related but separate independent agreements and by holding that

* Retired Senior Judge assigned to the Superior Court. 1 “An order overruling preliminary objections is an interlocutory order. The law is clear, however, that an order overruling preliminary objections that seek to compel arbitration is an interlocutory order appealable as of right pursuant to 42 Pa.C.S. § 7320(a)(1) and Pa.R.A.P. 311(a)(8).” In re Estate of Atkinson, 231 A.3d 891, 897-98 (Pa. Super. 2020). “Because this case was decided on preliminary objections, we rely on the facts as alleged in the complaint, including its exhibits.” Khawaja v. RE/MAX Central, 151 A.3d 626, 627 n.1 (Pa. Super. 2016) (citation omitted). We may cite to the parties’ reproduced record for their convenience.

Appellant waived its right to arbitration. Appellant concedes in its brief that the agreements are related, but argues that as a matter of law that the agreements are treated as separate. We agree and reverse.

We state the facts as pled in Appellant’s complaint. Appellant is a Chinese corporation, and Appellee is a Pennsylvania corporation. R.R. at 1a. On October 18, 2012, the parties executed a contract (October 2012 contract) in which Appellant was the exclusive agent of Appellee’s skincare products in China. Id. at 2a. The October 2012 contract contains a mandatory arbitration clause, which states in relevant part that “the parties shall resolve any dispute arising from this contract through negotiation. If no agreement can be reached, [the parties] both agree” to arbitration. Id. at 58a (formatting altered).

Per the October 2012 contract, Appellant paid Appellee $599,985.00 “for products and services and also advances for future products and services.” Id. at 2a. Appellee delivered goods and services worth around $354,811.13. Id. Appellant contends that after costs and other expenses, Appellee still owes Appellant at least $243,192.41. Id.

In a November 16, 2018 letter (2018 confirmation letter) signed by the parties, they agreed that Appellee owed Appellant $243,192.41:

[Appellant] and [Appellee] executed the [October 2012 contract].

[Appellant’s] financial records show we made a number of payments totaling $599,985.00 US dollars for the ordered goods pursuant to the above Agreement and [Appellee] has delivered goods and charged for the associated costs, which total $345,811.13 US dollars, as of October 12, 2018.

Our President Wang Qiong and your President Phyllis Hsieh hereby agree on the following accounts after their audit of the delivery of goods and the transfer of funds: . . . .

Id. at 79a. Attached to the letter were tables and exhibits listing financial transactions, which essentially showed that Appellee owed Appellant $243,192.41. See, e.g., id. at 91a.

On March 6, 2019, Appellee sent a letter to Appellant to terminate the October 2012 contract. Id. at 3a. Appellant countered that Appellee could not unilaterally terminate the October 2012 contract, but was willing to end the business relationship as long as Appellee repaid Appellant the amount still owed. Id.

Appellee failed to repay, however, which resulted in Appellant filling the instant complaint on September 4, 2019, against Appellee. Id. at 1a. Appellant sued Appellee for breach of the 2018 confirmation letter, unjust enrichment, conversion, and account stated. Id. at 1a-5a. Appellant requested damages in the amount owed of $243,192.41, plus interest, costs, and expenses. Id. at 5a.

On October 9, 2019, Appellee filed an answer, new matter, and counterclaims. Id. at 12a. Specifically, Appellee filed counterclaims for breach of the October 2012 contract and for unfair competition. Id. at 19a- 20a. On December 4, 2019, Appellant filed preliminary objections, which contended that Appellee’s counterclaims based on the October 2012 contract were subject to that contract’s mandatory arbitration clause. Id. at 36a, 40a.

On February 20, 2020, the trial court overruled Appellant’s preliminary objections and ordered Appellant to file an answer to Appellee’s counterclaims. Order, 2/20/20. In relevant part, the trial court concisely held that the “two alleged contracts are intertwined.” Id. at n.1.2 The trial court further held that Appellant, “[b]y initiating the instant action for breach of the [2018 confirmation letter] which would not exist without the [October 2012 contract, Appellant] has waived its right to demand arbitration on [Appellee’s] counterclaims.” Id.; accord Trial Ct. Op., 4/29/20, at 2-3.

On March 20, 2020, Appellant filed a timely notice of appeal.3 Appellant timely filed a court-ordered Pa.R.A.P. 1925(b) statement.

Appellant raises the following issue on appeal:

1. Did the trial court err as a matter of law by failing to recognize that the 2018 confirmation letter—an agreement with no arbitration provision—is separate and distinct from the [October 2012 contract]?

2. Did the trial court err as a matter of law in finding [Appellant]

intentionally waived the mandatory arbitration provision in the [October 2012 contract] when [Appellant] only asserted claims arising from a 2018 confirmation letter containing no such provision, and [Appellant] used its first opportunity to seek dismissal of counterclaims that are properly adjudicated through binding arbitration?

2The trial court cited no legal authorities in support of its holding or otherwise explained its legal reasoning on this point. 3 Meanwhile, on March 5, 2020, Appellant filed a motion for reconsideration. On March 25, 2020, the trial court dismissed Appellant’s motion for reconsideration as moot due to the pending appeal. Order, 3/25/20.

Appellant’s Brief at 5 (formatting altered).

In support of its first issue, Appellant argues that the 2018 confirmation letter is an agreement separate from the October 2012 contract. Id. at 13. In Appellant’s view, those two agreements are separate because there was no integration clause in the 2018 confirmation letter incorporating the October 2012 contract. Id. at 13-14. Appellant notes that the October 2012 contract “deals with the parties establishing their relationship six years [prior to the 2018 confirmation letter] and addresses events that might happen in the future, such as trademark usage, product purchasing, and ownership of goods outlined therein” and was made under circumstances different than the 2018 confirmation letter. Id. at 15. Appellant contends that because the 2018 confirmation letter stands independently and does not contain an arbitration provision, the parties cannot arbitrate any counterclaims related to the 2018 confirmation letter.4 Id. at 15.

The Atkinson Court set forth our standard of review as follows:

[W]e employ a two-part test to determine whether the trial court should have compelled arbitration. First, we examine whether a valid agreement to arbitrate exists. Second, we must determine whether the dispute is within the scope of the agreement.

Whether a written contract includes an arbitration agreement and whether the parties’ dispute is within the scope of the arbitration

Free access — add to your briefcase to read the full text and ask questions with AI

Chongqing Kangning v. Conrex Pharmaceutical Corp., (Pa. Ct. App. 2021).

Chongqing Kangning v. Conrex Pharmaceutical Corp. (Chongqing Kangning v. Conrex Pharmaceutical Corp.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Small v. Small
137 A.2d 870 (Superior Court of Pennsylvania, 1958)
Neville v. Scott
127 A.2d 755 (Superior Court of Pennsylvania, 1956)
O'DONNELL v. Hovnanian Enterprises, Inc.
29 A.3d 1183 (Superior Court of Pennsylvania, 2011)
Fell, R. v. 340 Associates, LLC
125 A.3d 75 (Superior Court of Pennsylvania, 2015)
David v. Veitscher Magnesitwerke Actien Gesellschaft
35 A.2d 346 (Supreme Court of Pennsylvania, 1943)
Donahue v. Philadelphia
41 A.2d 879 (Superior Court of Pennsylvania, 1944)
Wilson v. Viking Corp.
3 A.2d 180 (Superior Court of Pennsylvania, 1938)
Khawaja, H. v. Re/Max Central
151 A.3d 626 (Superior Court of Pennsylvania, 2016)
Nicholas, J. v. Hofmann, D.
158 A.3d 675 (Superior Court of Pennsylvania, 2017)
Maxatawny Township v. Kutztown Borough
113 A.3d 895 (Commonwealth Court of Pennsylvania, 2015)
Leinbach v. Wolle
61 A. 248 (Supreme Court of Pennsylvania, 1905)
International Milling Co. v. Hachmeister, Inc.
110 A.2d 186 (Supreme Court of Pennsylvania, 1955)
Richburg v. Palisades Collection LLC
247 F.R.D. 457 (E.D. Pennsylvania, 2008)
In Re:Est. of Atkinson, J., Appeal of: Wells Fargo
2020 Pa. Super. 87 (Superior Court of Pennsylvania, 2020)